Biochemistry Archives - Sanford Burnham Prebys

Dr. Zeng has over 20 years of drug discovery and development experience, including 8 years with biotech companies. Before joining industry, Dr. Zeng was a staff scientist at National Institute of Health where he studied the structure and function of G-protein coupled receptors (GPCR). His work included the identification of key motifs, which activate muscarinic receptors, as well as the first discovery and characterization of muscarinic receptor dimerization.

In 1999, he took a team leader position at Arena Pharmaceuticals Inc. in San Diego, California, where he worked on developing novel GPCR screening assay platforms and drug discovery projects. In 2004, he transitioned to principal scientist at Novasite Pharmaceuticals Inc. in San Diego, where he continued on different GPCR drug discovery projects.

Dr. Zeng joined St. Jude Children Research Hospital at Memphis, Tennessee in 2007 where he helped establish a world-class automation high throughput screening system and managed a screening and drug discovery team. The team pursued projects in all classes of targets. He went on to join Sanford Burnham Prebys in 2009, where he is Associate Director of High Throughput Screening and Compound Management.

Dr. Zeng received his PhD from the Faculty of Pharmacy of the Philips University of Marburg, Germany.

Career Highlights

2007-2009: Principal Scientist, Chemical Biology Department, St. Jude Children Research Hospital, Memphis, Tennessee
2004-2007: Principal Scientist, Novasite Pharmaceuticals Inc, San Diego, California
1999-2004: Team Leader, Arena Pharmaceuticals Inc, San Diego, California
1997-1999: Staff Scientist, NIDDK, NIH, Bethesda, Maryland

Select Publications

Showing 3 of 3

Guy Salvesen earned his PhD in biochemistry from Cambridge University in 1980. He conducted postdoctoral research at Strangeways Laboratory and MRC Laboratory of Molecular Biology in Cambridge, followed by further post-doctoral training at the University of Georgia. In 1991 he was appointed Assistant Professor at Duke University. Dr. Salvesen was recruited to Sanford-Burnham Medical Research Institute in 1996, where he is professor and director of the Apoptosis and Cell Death Research Program and dean of the Graduate School of Biomedical Sciences. He also holds an adjunct position as professor in the Department of Pathology at the University of California, San Diego.

Education

1981: PhD, Cambridge University, England, Biology
1977: B. Sc., London University, London, England, Microbiology

Other Appointments

Adjunct Professor, Department of Pathology, University of California, San Diego

Honors and Recognition

2014: Organizer, Keystone Meeting on Cell Death, February
2013: IUBMB Gold Medal Recipient, October
2010: Keynote Speaker, European Cell Death Organization Conference,
2010: Keynote Speaker, Gordon Research Conference on Cell Death
2009: Lifetime Achievement Award of the International Proteolysis Society
2008: Keynote Speaker, Queenstown Molecular Biology Conference
2008: Chair, Gordon Research Conference on Cell Death
2005: Helmut Holzer Memorial Prize
1999: International Proteolysis Society, Elected Secretary
1999: Keynote Speaker, Gordon Research Conference on Matrix Metalloproteinases
1988: American Association for the Study of Liver Diseases, State of the Art Lecture
1996: Chair, Gordon Research Conference on Proteolytic Enzymes and Their Inhibitors

Select Publications

Showing 1 of 1

Related Disease
HIV/AIDS, Infectious Diseases, Molecular Biology

Phenomena or Processes
Host-Pathogen Interactions, Infectious Disease Processes, Inflammation, Innate Immunity

Anatomical Systems and Sites
Immune System and Inflammation

Research Models
Clinical and Transitional Research, Computational Modeling, Human, Human Cell Lines, Mouse, Mouse Cell Lines, Primary Cells, Primary Human Cells

Techniques and Technologies
Biochemistry, Bioinformatics, Cellular and Molecular Imaging, Drug Discovery, Drug Efficacy, Gene Expression, Gene Knockout (Complete and Conditional), Gene Silencing, High-Throughput/Robotic Screening, RNA Interference (RNAi), Systems Biology

Select Publications

Showing 1 of 1

Xueqin (Sherine) Sun seeks to better understand the genetic and epigenetic underpinnings of cancers, using genome editing technologies, animal and patient-derived models, and other tools to develop more effective cancer therapies.

“My lab is interested in studying how DNA or the machinery that interprets it leads to the transformation of normal cells into cancerous cells and concurrently, their specific vulnerabilities. Identifying these intrinsic vulnerabilities and targeting them properly is profoundly important to developing effective cancer therapies.”

Another aspect of Sun’s work is understanding how cancer cells and tumors change their circumstances and environment to improve survival, including hiding from or repressing the immune system.

“Changes to DNA itself and the way how DNA is interpreted by cells can transform normal cells into cancer cells. And transformed cells propagate by enhancing the misinterpreted DNA information, which in turn becomes the Achilles’ heel of cancer cells. Our goal is to find out how DNA information is misinterpreted in different ways and how to correct it to halt cancer.”

At Sanford Burnham Prebys, Sun and colleagues will employ a host of leading-edge tools and approaches, including functional genomics, artificial intelligence, structural biology, large-scale drug screening, and advanced imaging/spatial technologies.

Sun conducted her postdoctoral fellowship at Cold Spring Harbor Laboratory under the guidance of Alea Mills, PhD, a professor at the National Cancer Institute-designated cancer center at Cold Spring Harbor.

She received her PhD from Wuhan University in China.

Select Publications

Showing 3 of 3

Timothy Huang completed his PhD at the University of Calgary (Canada) under Dr. Dallan Young, studying kinase pathways involved in mediating cell polarity in yeast. He studied mechanisms underlying actin cytoskeletal dysfunction in Alzheimer’s disease at Scripps with Dr. Gary Bokoch (La Jolla), before joining Dr. Huaxi Xu’s laboratory in 2012/2013.

Select Publications

Showing 3 of 3